Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization andin vivoantitumor activity
| Autor: | Zhuo Zhang, Chan Zhang, Liangqi Zhao |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Poly(3-hydroxybutyrate-co-3-hydroxyoctanoate)
Materials science Stereochemistry Chemistry Pharmaceutical Polyesters Pharmaceutical Science Nanoparticle Antineoplastic Agents macromolecular substances 02 engineering and technology 030226 pharmacology & pharmacy HeLa 03 medical and health sciences Drug Delivery Systems Folic Acid 0302 clinical medicine In vivo medicine Humans Doxorubicin Antitumor activity biology technology industry and agriculture General Medicine 021001 nanoscience & nanotechnology biology.organism_classification Polyester Drug Liberation Folate receptor Nanoparticles 0210 nano-technology HeLa Cells Nuclear chemistry medicine.drug |
| Zdroj: | Drug Delivery. 23:1830-1837 |
| ISSN: | 1521-0464 1071-7544 |
| DOI: | 10.3109/10717544.2015.1122675 |
| Popis: | Doxorubicin (DOX)-loaded folate-targeted poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) [P(HB-HO)] nanoparticles [DOX/FA-PEG-P(HB-HO) NPs] have potential application in clinical treatments for cervical cancer due to specific affinity of folate and folate receptor in HeLa cells.The aim of this study was to develop an optimized formulation for DOX/FA-PEG-P(HB-HO) NPs, and investigate the targeting and efficacies of the nanoparticles.DOX/FA-PEG-P(HB-HO) NPs were prepared by W1/O/W2 solvent extraction/evaporation method, and an orthogonal experimental design [L9 (3(4))] was applied to establish the optimum conditions. The physico-chemical characteristics, microscopic observation and in vivo antitumor study of the nanoparticles were evaluated.The optimum formulation was obtained with DOX 10% (w/v), FA-PEG-P(HB-HO) 6.5% (w/v), PVA 3%(w/v) and oil phase/internal water phase volume ratio of 3/1. The size distribution, drug loading and encapsulation efficiency of the optimized nanoparticles were 150-350 nm, 29.6 ± 2.9% and 83.5 ± 5.7%, respectively. In vitro release study demonstrated that 80% of the drug could release from the nanoparticles within 11 days. Furthermore, in vitro microscopic observation and in vivo antitumor study showed that DOX/FA-PEG-P(HB-HO) NPs could inhibit HeLa cells effectively, and the tumor inhibition rate (TIR) in vivo was 76.91%.DOX/FA-PEG-P(HB-HO) NPs have been successfully developed and optimized. In vitro drug release study suggested a sustained release profile. Moreover, DOX/FA-PEG-P(HB-HO) NPs could effectively inhibit HeLa cells with satisfying targeting, and reduce side effects and toxicity to normal tissues. DOX/FA-PEG-P(HB-HO) NPs were superior in terms of inhibiting HeLa tumor over non-targeted formulations therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|